These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1383063)

  • 41. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
    Esnouf RM; Stuart DI; De Clercq E; Schwartz E; Balzarini J
    Biochem Biophys Res Commun; 1997 May; 234(2):458-64. PubMed ID: 9177293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations.
    Schäfer W; Friebe WG; Leinert H; Mertens A; Poll T; von der Saal W; Zilch H; Nuber B; Ziegler ML
    J Med Chem; 1993 Mar; 36(6):726-32. PubMed ID: 7681480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4.
    Ho W; Kukla MJ; Breslin HJ; Ludovici DW; Grous PP; Diamond CJ; Miranda M; Rodgers JD; Ho CY; De Clercq E
    J Med Chem; 1995 Mar; 38(5):794-802. PubMed ID: 7877144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives.
    Darnag R; Mostapha Mazouz EL; Schmitzer A; Villemin D; Jarid A; Cherqaoui D
    Eur J Med Chem; 2010 Apr; 45(4):1590-7. PubMed ID: 20110136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
    Sapre NS; Gupta S; Pancholi N; Sapre N
    J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Mao C; Vig R; Venkatachalam TK; Sudbeck EA; Uckun FM
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2213-8. PubMed ID: 9873515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.
    Ichimura H; Levy JA
    Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Monforte AM; Logoteta P; De Luca L; Iraci N; Ferro S; Maga G; De Clercq E; Pannecouque C; Chimirri A
    Bioorg Med Chem; 2010 Feb; 18(4):1702-10. PubMed ID: 20097079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
    Hanasaki Y; Watanabe H; Katsuura K; Takayama H; Shirakawa S; Yamaguchi K; Sakai S; Ijichi K; Fujiwara M; Konno K
    J Med Chem; 1995 Jun; 38(12):2038-40. PubMed ID: 7540208
    [No Abstract]   [Full Text] [Related]  

  • 52. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
    EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents.
    Barreca ML; Chimirri A; De Luca L; Monforte AM; Monforte P; Rao A; Zappalà M; Balzarini J; De Clercq E; Pannecouque C; Witvrouw M
    Bioorg Med Chem Lett; 2001 Jul; 11(13):1793-6. PubMed ID: 11425562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiviral action of oligodeoxyguanylic acids against human immunodeficiency virus type 1.
    Fujihashi T; Sakata T; Kaji A; Kaji H
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):461-71. PubMed ID: 7543270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.
    Pauwels R; Andries K; Debyser Z; Van Daele P; Schols D; Stoffels P; De Vreese K; Woestenborghs R; Vandamme AM; Janssen CG
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1711-5. PubMed ID: 7680476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability.
    Kim J; Ok T; Park C; So W; Jo M; Kim Y; Seo M; Lee D; Jo S; Ko Y; Choi I; Park Y; Yoon J; Ju MK; Ahn J; Kim J; Han SJ; Kim TH; Cechetto J; Nam J; Liuzzi M; Sommer P; No Z
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2522-6. PubMed ID: 22374216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. QSAR modeling with the electrotopological state: TIBO derivatives.
    Huuskonen J
    J Chem Inf Comput Sci; 2001; 41(2):425-9. PubMed ID: 11277732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors.
    Yang G; Song Q; Charles M; Drosopoulos WC; Arnold E; Prasad VR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):326-33. PubMed ID: 8601218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
    De Clercq E; Yamamoto N; Pauwels R; Baba M; Schols D; Nakashima H; Balzarini J; Debyser Z; Murrer BA; Schwartz D
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5286-90. PubMed ID: 1608936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.